Terumo Acquires CE Marking for Ultimaster Tansei Drug Eluting Stent Available in Europe Starting in May

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

April 25, 2018: Today Terumo Corporation announced that it acquired CE marking for the Ultimaster™ Tansei™ drug-eluting stent (DES). Looking ahead, Terumo will begin sales of the product in Europe in May 2018.

On January 24, 2018, Terumo Corporation received approval to manufacture and sell Ultimaster Tansei in Japan, and it plans to release the product in the second half of fiscal 2018.

For the Ultimaster Tansei, Terumo inherited the same stent, drug, polymer, and coating methods used for its predecessor, the Ultimaster DES, which was launched in 2014, while making improvements to the tip and shaft in order to facilitate stent delivery in complex lesions. Terumo aimed to enhance the product’s usability and make it easier to navigate the stent through the blood vessels by creating a tip with a structure using highly durable yet still flexible materials, and by designing the shaft to have highly kink-resistance, providing exceptional pushability.

Available in a wide range of sizes, Ultimaster Tansei enables a broad variety of treatment options. Terumo will offer a total of 54 size lineup with stent diameter ranging from 2.25 to 4.0 mm, and lengths from 9 to 38 mm in addition to the standard length of 21 mm. Accordingly, the new product will facilitate an extensive range of treatments for complex lesions.

Terumo has been strategically developing the DES under its Mid- to Long-term Growth Strategy. Following the release of the new Ultimaster Tansei, Terumo plans to launch more products with improved stent designs as metal DES in the Ultimaster series, with the goals of securing the number-one share of the DES market in Japan and doubling its market share in Europe and emerging countries. While offering optimal therapeutic alternatives to healthcare professionals, Terumo will work to contribute to improving the quality of life of patients worldwide in the future.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.